NCT02227459View on ClinicalTrials.gov

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)
Interventions
DRUG

ND-L02-s0201 Injection

Trial Locations (2)

78215

Texas Liver Institute, Austin

Unknown

Tokuda Hospital, Sofia

Sponsors

Collaborators (1)

Nitto Denko Corporation
All Listed Sponsors
collaborator

Nitto Denko Corporation

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY